Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 78 results for menopause

  1. Research recommendations

    subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause is inadequate in quality and quantity. Therefore,...

  2. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    symptoms. Source guidance details Comes from guidance Menopause: diagnosis and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  3. Effects of HRT on dementia risk:- What are the effects of early HRT use on the risk of dementia?

    natural menopause, including women with premature ovarian insufficiency. Source guidance details Comes from guidance...

    Research recommendation
    Published
    11 December 2015

  4. Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

    indicated. Source guidance details Comes from guidance Menopause: diagnosis and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  5. Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

    Women with premature ovarian insufficiency can experience the effects of menopause for most of their adult life. This can lead to...

    Research recommendation
    Published
    11 December 2015

  6. Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopausal symptoms in women who have had treatment for breast cancer?

    treatment. Source guidance details Comes from guidance Menopause: diagnosis and management Number NG23 Date issued

    Research recommendation
    Published
    11 December 2015

  7. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

    NICE guideline
    Published
    20 October 2015
    View recommendations

    Sections for NG16

  8. Press and media

    people at risk. Menopause Most women experience some symptoms with menopause. The depletion of oestrogen associated with...

    News
    Published
    6 July 2015

  9. Benefits of MRI surveillance in women over 50 years:- Research is recommended to establish the risk and benefits of MRI surveillance compared with mammography in women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density. [new 2013]

    Although breast density decreases with age, and particularly after the menopause, there is no sudden change at any particular age. For...

    Research recommendation
    Published
    9 June 2015

  10. Obesity prevention (CG43)

    This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.

    Clinical guideline
    Last updated
    13 March 2015
    View recommendations

    Sections for CG43

  11. Ovarian cancer (QS18)

    This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 May 2012
    View quality statements

    Sections for QS18

  12. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037

    Awaiting development [GID-TA11059] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC

    Medical technologies guidance
    In development

  14. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917

    Awaiting development [GID-TA11428] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development